Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
carepen vet (caremast vet) spenalyf, dreifa 600 mg
vetcare oy - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
carepen vet spenalyf, dreifa 600 mg
vetcare ltd.* - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
streptocillin vet. stungulyf, dreifa
boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
depomycine, vet. stungulyf, dreifa
intervet international b.v.* - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
geepenil vet. stungulyfsstofn og leysir, lausn 24 g
orion corporation - benzylpenicillinum natríum - stungulyfsstofn og leysir, lausn - 24 g
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
penovet vet. stungulyf, dreifa 300 .000 a.e./ml
boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum - stungulyf, dreifa - 300 .000 a.e./ml
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
procapen vet spenalyf, dreifa 3 g
animedica gmbh* - benzylpenicillinprocainum - spenalyf, dreifa - 3 g
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
benestermycin vet. spenalyf, smyrsli
boehringer ingelheim vetmedica gmbh* - framycetinum súlfat; benethaminum penicillinum inn; penethamate hydroiodide ban - spenalyf, smyrsli
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
penethaone vet (penethamate) stungulyfsstofn og leysir, dreifa 236,3 mg/ml
divasa-farmavic s.a. - penethamate hydriodide - stungulyfsstofn og leysir, dreifa - 236,3 mg/ml
Եվրոպական Միություն -
իսլանդերեն -
EMA (European Medicines Agency)
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.